Guggenheim Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Guggenheim Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,028	Closed	-$8K	–	2206
2020 Q4	$8K	Hold	12,028	–	–	﹤0.01%	2038
2020 Q3	$27K	Hold	12,028	–	–	﹤0.01%	1910
2020 Q2	$43K	Hold	12,028	–	–	﹤0.01%	1855
2020 Q1	$46K	Hold	12,028	–	–	﹤0.01%	1799
2019 Q4	$36K	Buy	+12,028	New	+$31.3K	﹤0.01%	2054

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Guggenheim Capital's BMY.RT Position: Q1 2021 in Review

Guggenheim Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,028 shares — an estimated $8K sold.

Guggenheim Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $46K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Guggenheim Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Guggenheim Capital sold 12,028 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
Guggenheim Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Guggenheim Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $46K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Guggenheim Capital's 13F filing for Q1 2021, filed 13 May 2021.